Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Monte Rosa Therapeutics, Inc. - Common Stock (NQ:GLUE)

14.36 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 14.36
Bid (Size) 13.45 (100)
Ask (Size) 14.53 (100)
Prev. Close 14.36
Today's Range 14.36 - 14.36
52wk Range 3.500 - 14.62
Shares Outstanding 49,383,711
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Inc (NASDAQ:GLUE) Q3 2025 Earnings Beat Estimates, Stock Rises ↗
Monte Rosa Therapeutics (GLUE) Q3 2025 earnings crushed estimates, with revenue of $12.8M. The stock is up on strong results and a cash runway extending into 2028. 
Via Chartmill
Topics Earnings

Performance

YTD
+102.0%
+102.0%
1 Month
+42.9%
+42.9%
3 Month
+214.9%
+214.9%
6 Month
+249.4%
+249.4%
1 Year
+90.5%
+90.5%

More News

Read More
News headline image
Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Stock Scores Biggest Gain In Nearly A Year On $5.7B Novartis Deal For Immune-Mediated Diseases ↗
Via Stocktwits
News headline image
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dave & Buster's Entertainment Posts Downbeat Results, Joins Adtran Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
Why Webtoon Entertainment Shares Are Trading Higher By 48%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Here are the top movers in Monday's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
News headline image
Which stocks are moving on Monday? ↗
Via Chartmill
News headline image
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments ↗
Via Benzinga
News headline image
Monday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Monday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa (GLUE) Q2 Revenue Jumps 394% ↗
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Monte Rosa Therapeutics Inc (NASDAQ:GLUE) Q2 2025 Earnings: Revenue Surges, Loss Narrower Than Expected ↗
Via Chartmill
News headline image
Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
News headline image
Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Monte Rosa Therapeutics, Inc. - Common Stock publicly traded?
Yes, Monte Rosa Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Monte Rosa Therapeutics, Inc. - Common Stock trade on?
Monte Rosa Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Monte Rosa Therapeutics, Inc. - Common Stock?
The ticker symbol for Monte Rosa Therapeutics, Inc. - Common Stock is GLUE on the Nasdaq Stock Market
What is the current price of Monte Rosa Therapeutics, Inc. - Common Stock?
The current price of Monte Rosa Therapeutics, Inc. - Common Stock is 14.36
When was Monte Rosa Therapeutics, Inc. - Common Stock last traded?
The last trade of Monte Rosa Therapeutics, Inc. - Common Stock was at 11/14/25 04:00 PM ET
What is the market capitalization of Monte Rosa Therapeutics, Inc. - Common Stock?
The market capitalization of Monte Rosa Therapeutics, Inc. - Common Stock is 709.15M
How many shares of Monte Rosa Therapeutics, Inc. - Common Stock are outstanding?
Monte Rosa Therapeutics, Inc. - Common Stock has 709M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.